Cereno Scientific publishes update and study protocol for the FDA approved Expanded Access Program for CS1 in PAH
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced the study protocol for the Expanded Access Program (EAP) for its lead candidate drug, the HDAC inhibitor CS1, in the rare disease Pulmonary Arterial Hypertension. The EAP will support long-term documentation of safety and efficacy data of CS1 treatment in the Phase II study in PAH.As previously reported, investigators have shown substantial interest in the EAP with two-thirds of the patients, having completed the study or are currently on